The new cell therapy facility will be located on Bristol Myers Squibb’s current 89-acre Devens campus that supports process development, clinical manufacturing and commercial manufacturing for biologics medicines, including an immuno-oncology medicine. Expanding our global footprint is critical to supplying these transformational products to patients around the world.” in the U.S., as well as external manufacturing facilities in the U.S., Europe and Japan. “Bristol Myers Squibb has designed a reliable manufacturing and global supply chain network comprised of internal manufacturing facilities, which include Bothell, Wash., Summit, N.J., and Warren, N.J. “Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital systems,” said Ann Lee, Ph.D., head, Cell Therapy Development & Operations, Bristol Myers Squibb. ![]() Each batch of engineered T cells is made for infusion back to the original cancer patient, and it is critical for companies to develop reliable quality supply, and rapid turnaround time. Manufacturing cell therapies is both operationally and technically complex because they are manufactured uniquely for each individual patient, using a patient’s own T cells as the starting material. The Devens site will be equipped to enable quick ramp up of capacity for clinical and commercial cell therapy products. The 244,000 square foot facility adds to the company’s already established state-of-the-art cell therapy manufacturing network with cutting-edge technologies and highly trained manufacturing teams. The Devens site is the latest investment from Bristol Myers Squibb as the company expands its robust global manufacturing network.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |